FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and specifically to a polypeptide compound of a triple agonist GLP-1/GIP/GCG R, or a salt thereof, or a solvate thereof, as well as a composition containing it.
EFFECT: invention is effective for treating metabolic syndrome, when preparing medicinal agents for reducing apoptosis β-cells of pancreatic islets, increase in number β-cells of pancreatic islets and improved function of islet cells of pancreas, when preparing medicinal agents for improving blood lipids, reducing fatty deposits in the liver, inhibiting the development of liver inflammation, preventing or treating non-alcoholic fatty liver disease, when preparing medicinal agents for preventing or treating metabolic disorders and related complications, when preparing medicinal agents for treating dyslipidemia and related diseases, as well as neurodegenerative diseases, as well as in the preparation of drugs for the treatment of bone diseases associated with endocrine disorders, metabolic disorders, kidney diseases.
26 cl, 10 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
Authors
Dates
2025-01-27—Published
2022-05-18—Filed